ALK-Abelló A/S [clinicaltrials_resource:51036728df08e9dc253fab245e130e6e]
affiliation [clinicaltrials_vocabulary:affiliation]
Exposure Chamber Trial With Cat Immunotherapy [clinicaltrials:NCT00987909]Comparison of Different Up-dosing Schedules With Osiris Phleum Pratense [clinicaltrials:NCT01425788]House Dust Mite Treatment of Asthma. The MITRA Trial House Dust Mite Treatment of Asthma [clinicaltrials:NCT01433523]A Dose-response Evaluation of the SQ Tree SLIT-tablet Using an Environmental Exposure Chamber [clinicaltrials:NCT02481856]
collaborator [clinicaltrials_vocabulary:collaborator]
A Trial of the ALK Grass Tablet in Subjects With Hayfever [clinicaltrials:NCT00227279]Assessment of Grazax® Treatment Compliance [clinicaltrials:NCT00293046]Tolerability of Grazax-R in Children [clinicaltrials:NCT00298701]Tolerability of ALK Grass Tablet in Children [clinicaltrials:NCT00310453]clinicaltrials:NCT00310466Efficacy and Safety Trial of ALK-depot SQ Mites in Subjects With Atopic Dermatitis [clinicaltrials:NCT00310492]Safety of ALK Ragweed Tablet [clinicaltrials:NCT00330083]Efficacy and Safety Trial of the ALK HDM Tablet in House Dust Mite Allergic Subjects [clinicaltrials:NCT00389363]Efficacy and Safety of Grazax in Children [clinicaltrials:NCT00408616]Changes in the Immune Response and Skin Reactivity of Grass Pollen Allergic Patients Treated With ALK Grass Tablets [clinicaltrials:NCT00413556]A Trial of Grazax in Subjects With Hayfever [clinicaltrials:NCT00421655]Efficacy and Safety Trial of Subcutaneous Immunotherapy in Mite Induced Asthma [clinicaltrials:NCT00492076]Tolerability of ALK Tree Tablet [clinicaltrials:NCT00535639]clinicaltrials:NCT00633919A Phase III Trial Assessing the Pharmacodynamic Effect and the Tolerability of Grazax Treatment [clinicaltrials:NCT00773240]Intraseasonal Short-time Up-dosing With Alutard SQ Grasses [clinicaltrials:NCT00807547]Study on Pharmacodynamic Parameter and Tolerability With Subcutaneous Immunotherapy in Grass Pollen Allergic Patients [clinicaltrials:NCT00857779]Exposure Chamber Trial With Cat Immunotherapy [clinicaltrials:NCT00987909]Grazax Asthma Prevention [clinicaltrials:NCT01061203]Efficacy and Tolerability of Two Different Administration Routes With SLITonePLUS Birch [clinicaltrials:NCT01191359]Comparison of Different Up-dosing Schedules With Osiris [clinicaltrials:NCT01240954]Comparison of Different Up-dosing Schedules With Osiris Phleum Pratense [clinicaltrials:NCT01425788]Tolerability of Grazax in Patients With Hayfever in Real Life Settings [clinicaltrials:NCT01433510]House Dust Mite Treatment of Asthma. The MITRA Trial House Dust Mite Treatment of Asthma [clinicaltrials:NCT01433523]Avanz Phleum Pratense Maintenance Dose [clinicaltrials:NCT01438827]clinicaltrials:NCT01454531A One Year Trial Evaluating the Safety and Efficacy of the ALK House Dust Mite Allergy Tablet [clinicaltrials:NCT01454544]An Open Trial to Assess the Tolerability of AVANZ Mite Mix Immunotherapy [clinicaltrials:NCT01568190]Efficacy and Safety Trial of Pangramin SLIT HDM-mix in Subjects With House Dust Mite Induced Rhinitis [clinicaltrials:NCT01603056]An Open Trial to Assess the Tolerability of AVANZ Olive Immunotherapy [clinicaltrials:NCT01674595]A Dose-response Evaluation of ALK (the Sponsor) Tree Allergy Immunotherapy Tablet [clinicaltrials:NCT01675791]Compliance to the Treatment With GRAZAX® Tablets in Patients With Seasonal Grass Pollen Rhinoconjunctivitis [clinicaltrials:NCT01728285]A Dose Response Evaluation of SLITone Ultra HDM Mix Immunotherapy [clinicaltrials:NCT01728298]A Trial Evaluating Tolerability of Grazax Treatment in Combination With Antihistamine [clinicaltrials:NCT01740284]Molecular and Cellular Mechanism in the Course of Immunotherapy With a Phleum Pratense Oral Lyophilisate [clinicaltrials:NCT01854736]An Open Trial to Assess the Tolerability of AVANZ® Salsola Immunotherapy [clinicaltrials:NCT02065856]An Open Trial to Assess the Tolerability of AVANZ® Cupressus Immunotherapy [clinicaltrials:NCT02069535]Evaluation of the Efficacy and Safety of AVANZ® Phleum Pratense in Grass Pollen-induced Allergic Rhinitis During Controlled Exposure in an Environmental Challenge Chamber [clinicaltrials:NCT02166268]Molecular and Cellular Mechanism in Rhinitis Allergic Patients Treated With GRAZAX® [clinicaltrials:NCT02437786]A Dose-response Evaluation of the SQ Tree SLIT-tablet Using an Environmental Exposure Chamber [clinicaltrials:NCT02481856]
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
organization [clinicaltrials_vocabulary:organization]
A Trial of the ALK Grass Tablet in Subjects With Hayfever [clinicaltrials:NCT00227279]Assessment of Grazax® Treatment Compliance [clinicaltrials:NCT00293046]Tolerability of Grazax-R in Children [clinicaltrials:NCT00298701]Tolerability of ALK Grass Tablet in Children [clinicaltrials:NCT00310453]clinicaltrials:NCT00310466Efficacy and Safety Trial of ALK-depot SQ Mites in Subjects With Atopic Dermatitis [clinicaltrials:NCT00310492]Safety of ALK Ragweed Tablet [clinicaltrials:NCT00330083]Efficacy and Safety Trial of the ALK HDM Tablet in House Dust Mite Allergic Subjects [clinicaltrials:NCT00389363]Efficacy and Safety of Grazax in Children [clinicaltrials:NCT00408616]Changes in the Immune Response and Skin Reactivity of Grass Pollen Allergic Patients Treated With ALK Grass Tablets [clinicaltrials:NCT00413556]A Trial of Grazax in Subjects With Hayfever [clinicaltrials:NCT00421655]Efficacy and Safety Trial of Subcutaneous Immunotherapy in Mite Induced Asthma [clinicaltrials:NCT00492076]Tolerability of ALK Tree Tablet [clinicaltrials:NCT00535639]clinicaltrials:NCT00633919A Phase III Trial Assessing the Pharmacodynamic Effect and the Tolerability of Grazax Treatment [clinicaltrials:NCT00773240]Intraseasonal Short-time Up-dosing With Alutard SQ Grasses [clinicaltrials:NCT00807547]Study on Pharmacodynamic Parameter and Tolerability With Subcutaneous Immunotherapy in Grass Pollen Allergic Patients [clinicaltrials:NCT00857779]Exposure Chamber Trial With Cat Immunotherapy [clinicaltrials:NCT00987909]Grazax Asthma Prevention [clinicaltrials:NCT01061203]Efficacy and Tolerability of Two Different Administration Routes With SLITonePLUS Birch [clinicaltrials:NCT01191359]Comparison of Different Up-dosing Schedules With Osiris [clinicaltrials:NCT01240954]Comparison of Different Up-dosing Schedules With Osiris Phleum Pratense [clinicaltrials:NCT01425788]Tolerability of Grazax in Patients With Hayfever in Real Life Settings [clinicaltrials:NCT01433510]House Dust Mite Treatment of Asthma. The MITRA Trial House Dust Mite Treatment of Asthma [clinicaltrials:NCT01433523]Avanz Phleum Pratense Maintenance Dose [clinicaltrials:NCT01438827]clinicaltrials:NCT01454531A One Year Trial Evaluating the Safety and Efficacy of the ALK House Dust Mite Allergy Tablet [clinicaltrials:NCT01454544]An Open Trial to Assess the Tolerability of AVANZ Mite Mix Immunotherapy [clinicaltrials:NCT01568190]Efficacy and Safety Trial of Pangramin SLIT HDM-mix in Subjects With House Dust Mite Induced Rhinitis [clinicaltrials:NCT01603056]An Open Trial to Assess the Tolerability of AVANZ Olive Immunotherapy [clinicaltrials:NCT01674595]A Dose-response Evaluation of ALK (the Sponsor) Tree Allergy Immunotherapy Tablet [clinicaltrials:NCT01675791]Compliance to the Treatment With GRAZAX® Tablets in Patients With Seasonal Grass Pollen Rhinoconjunctivitis [clinicaltrials:NCT01728285]A Dose Response Evaluation of SLITone Ultra HDM Mix Immunotherapy [clinicaltrials:NCT01728298]A Trial Evaluating Tolerability of Grazax Treatment in Combination With Antihistamine [clinicaltrials:NCT01740284]Molecular and Cellular Mechanism in the Course of Immunotherapy With a Phleum Pratense Oral Lyophilisate [clinicaltrials:NCT01854736]An Open Trial to Assess the Tolerability of AVANZ® Salsola Immunotherapy [clinicaltrials:NCT02065856]An Open Trial to Assess the Tolerability of AVANZ® Cupressus Immunotherapy [clinicaltrials:NCT02069535]Evaluation of the Efficacy and Safety of AVANZ® Phleum Pratense in Grass Pollen-induced Allergic Rhinitis During Controlled Exposure in an Environmental Challenge Chamber [clinicaltrials:NCT02166268]Molecular and Cellular Mechanism in Rhinitis Allergic Patients Treated With GRAZAX® [clinicaltrials:NCT02437786]A Dose-response Evaluation of the SQ Tree SLIT-tablet Using an Environmental Exposure Chamber [clinicaltrials:NCT02481856]
source [clinicaltrials_vocabulary:source]
ALK-Abelló A/S [clinicaltrials_resource:51036728df08e9dc253fab245e130e6e]
Bio2RDF identifier
51036728df08e9dc253fab245e130e6e
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:51036728df08e9dc253fab245e130e6e
organization [clinicaltrials_vocabulary:organization]
identifier
clinicaltrials_resource:51036728df08e9dc253fab245e130e6e
title
ALK-Abelló A/S
@en
type
label
ALK-Abelló A/S [clinicaltrials_resource:51036728df08e9dc253fab245e130e6e]
@en